Literature DB >> 24334311

How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis.

Bushra Ahmed1, Andrew Bush1, Jane C Davies2.   

Abstract

Respiratory infections are the leading cause of morbidity and mortality in cystic fibrosis. Certain bacteria, such as Pseudomonas aeruginosa, are associated with a worse clinical outcome than others, but can be completely eradicated if identified and treated early. The diagnosis of lower respiratory tract infections can be challenging in the non-expectorating patient, in whom upper airway samples, such as cough swabs, are a surrogate for lower airway sampling. However, the results of these often do not fit with the clinical picture, presenting a management dilemma. Frequently, clinicians are faced with a negative culture result in a progressively symptomatic patient and vice versa. When judging the clinical significance of a positive upper airway culture result in an asymptomatic patient, it is important to consider the prognostic significance of the organism cultured. Given that the reported sensitivity of upper airway swabs (which includes throat swabs) is variable, ranging from 35.7% to 71% for Pseudomonas aeruginosa, 50% to 86% for Staphylococcus aureus and 11% to 92% for Haemophilus influenza, upper airway samples may fail to identify lower airway infections. Therefore, in symptomatic children, a repeatedly negative upper airway swab should not be considered as reassuring, and alternative sampling methods, such as induced sputum or bronchoalveolar lavage, should be considered. Here we use some examples of common scenarios to illustrate how best to use bacterial cultures to aid management decisions in cystic fibrosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Cystic Fibrosis; Respiratory

Mesh:

Year:  2013        PMID: 24334311     DOI: 10.1136/archdischild-2012-303408

Source DB:  PubMed          Journal:  Arch Dis Child Educ Pract Ed        ISSN: 1743-0585            Impact factor:   1.309


  4 in total

Review 1.  An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.

Authors:  John A King; Anna-Louise Nichols; Sian Bentley; Siobhan B Carr; Jane C Davies
Journal:  Paediatr Drugs       Date:  2022-05-16       Impact factor: 3.022

2.  Pseudomonas aeruginosa in the Cystic Fibrosis Lung.

Authors:  John King; Ronan Murphy; Jane C Davies
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Throat Swabs and Sputum Culture as Predictors of P. aeruginosa or S. aureus Lung Colonization in Adult Cystic Fibrosis Patients.

Authors:  Darius Seidler; Mary Griffin; Amanda Nymon; Katja Koeppen; Alix Ashare
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

4.  Resistance Pattern of Antibiotics in Patient Underwent Open Heart Surgery With Nosocomial Infection in North of Iran.

Authors:  Alireza Davoudi; Narges Najafi; Shahriar Alian; Atefe Tayebi; Fatemeh Ahangarkani; Samaneh Rouhi; Amirhosein Heydari
Journal:  Glob J Health Sci       Date:  2015-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.